Our Model
How we close the gap.
Creating value beyond molecules.
Amigen's model is built on a single insight: the hardest part of bringing a medicine to patients — the science — has already been done. We take it from there.
Approval risk only. Never development risk.
Creating value beyond molecules.
Every therapy we pursue has already cleared rigorous regulatory standards in established markets — the European Medicines Agency, the Therapeutic Goods Administration (Australia), Health Canada, Medsafe (New Zealand), ANVISA (Brazil), or equivalent authorities. The clinical evidence is established. The safety profile is known. The molecule is proven.
What remains is the work of local registration: navigating the regulatory pathway in each target market, assembling the dossier, managing the review process, and securing approval. That is the risk Amigen takes on — and the risk we are built to manage.
For our originator partners, this means emerging market entry without the complexity, cost, or distraction of managing unfamiliar regulatory environments. For patients, it means access to therapies that would otherwise remain out of reach for years.
The Process
From proven to accessible.
Identify
We identify the right therapies.
Our pipeline starts with rigorous selection. We look for therapies that are already approved in established markets, that address meaningful unmet need in our target geographies, and where a genuine cost advantage exists for the local market. Quality and safety are non-negotiable — we never trade one for the other.
Established market approval
EMA, TGA, Health Canada, Medsafe, ANVISA, or equivalent
Meaningful unmet need
Conditions underserved in target markets
Cost advantage
Accessible pricing without quality compromise
Regulatory pathway clarity
Viable local registration route confirmed
In-License
We secure in-licensing rights.
Once a therapy meets our criteria, we approach the originator to negotiate in-licensing rights for our target markets. We structure agreements that work for both sides: the originator gains a capable, committed partner for markets they cannot efficiently serve themselves; Amigen gains the rights to register and commercialise the therapy locally.
Territory-specific rights
Middle East, Africa, and selected emerging markets
Regulatory data access
Full dossier and clinical package
Commercial terms
Structured for long-term partnership
Post-approval obligations
Pharmacovigilance and lifecycle management
Register
We navigate local approval.
This is where Amigen's core capability sits. Our regulatory team manages the full local registration process — from dossier preparation and submission to agency liaison, query response, and final approval. We know the requirements, the timelines, and the nuances of each market we operate in. We carry this process end to end.
Dossier preparation
CTD-format submissions adapted for local requirements
Agency liaison
Direct engagement with national health authorities
Query management
Rapid, accurate responses to regulatory questions
Approval tracking
End-to-end timeline management
Deliver
We bring the therapy to market.
Approval is the milestone, not the destination. With registration secured, we build the commercial infrastructure to make access real: distribution partnerships, pricing strategy, market access engagement, and ongoing pharmacovigilance. The therapy reaches the patients it was always intended for.
Distribution
Local and regional supply chain partnerships
Market access
Payer and formulary engagement
Pricing strategy
Positioned for sustainable access
Pharmacovigilance
Ongoing safety monitoring and reporting
The Advantage
Why this model works.
For originators, CDMOs & CMOs
Whether you are a pharmaceutical originator, a CDMO, or a CMO with a unique product, emerging market entry is complex, expensive, and distracting. Amigen provides a single, accountable partner who handles market analysis, licensing structuring, regulatory execution, and commercialisation — without you needing to build local infrastructure.
For regional companies & distributors
Regional companies seeking access to innovative therapies or APIs benefit from Amigen's business intelligence, due diligence, and partnership structuring capabilities — helping them identify the right assets, evaluate them rigorously, and structure commercially sound agreements.
For patients and health systems
When proven therapies reach more patients, the evidence base grows, health systems improve, and the case for continued pharmaceutical innovation in emerging markets strengthens. Amigen's model creates value that compounds across the full value chain.
A product you want to bring to emerging markets?
Whether you are an originator, a CDMO, or a CMO with a unique product ready for global licensing — if you are looking for a partner to handle registration and commercialisation in emerging markets, we should talk.